Savara Inc SVRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
-
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
-
Savara Announces New Employment Inducement Grant
-
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
-
Savara Says FDA Has No Plans for Advisory Meeting for Lung Disease Treatment Application
Trading Information
- Previous Close Price
- $4.74
- Day Range
- $4.44–4.77
- 52-Week Range
- $3.50–7.01
- Bid/Ask
- $4.46 / $4.76
- Shares Outstanding
- 205.46M
- Market Cap
- $914.30M
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 70
- Website
- https://www.savarapharma.com
Valuation
|
Metric
|
SVRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.36 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SVRA
|
|---|---|
Quick Ratio | 9.89 |
Current Ratio | 10.13 |
Interest Coverage | — |
Quick Ratio
SVRA
Profitability
|
Metric
|
SVRA
|
|---|---|
Return on Assets (Normalized) | −57.64% |
Return on Equity (Normalized) | −75.94% |
Return on Invested Capital (Normalized) | −65.16% |
Return on Assets
SVRA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#FR<?N | LOCK|!#?h | $127B | |||
| Moderna Inc
MRNA
| LOCK|<XdZrw | LOCK|q@ | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&b&@wtp | LOCK|ps!W | $81B | |||
| argenx SE ADR
ARGX
| LOCK|DNZv%?G | LOCK|H% | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Y%Hx<Z | LOCK|!d | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|f^@^VD< | LOCK|mcSMg | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#$SHbSn? | LOCK|??H& | $27B | |||
| Incyte Corp
INCY
| LOCK|@h$&q? | LOCK|V% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|f<&@?F | LOCK|c%q | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|K?c?$!y | LOCK|cm | $14B |
United States